National Surveillance Network Would De-Identify Adverse Events Via 3rd Party
This article was originally published in The Gray Sheet
Executive Summary
Adverse event data would be de-identified by a third-party before submission to FDA under the agency's proposed pilot reporting system, according to Center for Devices and Radiological Health (CDRH) Office of Surveillance and Biometrics Deputy Director Susan Gardner.
You may also be interested in...
FDA Sentinel Program Increases Adverse Event Reporting By User Facilities
The average level of medical device adverse event reporting increased significantly under FDA's one-year Sentinel feasibility study concluded last year, according to a report submitted June 16 by Coda, the contractor organization facilitating the pilot.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.